Literature DB >> 19099499

Targeting the urokinase plasminogen activator receptor with synthetic self-assembly nanoparticles.

Ming Wang1, Dennis W P M Löwik, Andrew D Miller, Maya Thanou.   

Abstract

Targeting specific receptors is attracting growing interest in the fields of drug delivery and gene therapy for cancer treatment. The urokinase plasminogen activator receptor (uPAR) is overexpressed on many tumors,particularly that of prostate and breast cancers. The aim of this study is to design, prepare, and characterize a synthetic self-assembled nanoparticle that presents targeting ligands at a certain conformation and molar ratio onthe surface of the particles. Here, we describe the synthesis of a novel uPAR targeting ligand consisting of an 11-amino-acid sequence named U11 peptide modified with an alkyl chain to form an U11 peptide-lipid amphiphile.This peptide-lipid is inserted into the outer layer of a parent stealth liposome by post-modification to derive a U11 peptide-targeted nanoparticle. We demonstrate that the peptide moieties become separated into more singular conformations as they are inserted into a liposome membrane, rendering them to be sufficiently biologically active to observe specific receptor-mediated endocytosis (RME) and delivery of plasmid DNA to uPAR positive cells (DU145 cells). The U11 peptide targeted nanoparticle transfection of DU145 cells is essentially 10-fold higher compared to transfection achieved by nanoparticles having a scrambled peptide sequence on their surface.U11 peptide targeted nanoparticles also proved to be uPAR-specific, as they did not improve transfection levels on the uPAR-negative cell line, HEK293.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19099499     DOI: 10.1021/bc8001908

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  12 in total

1.  Targeted Nanodelivery of Drugs and Diagnostics.

Authors:  Margaret A Phillips; Martin L Gran; Nicholas A Peppas
Journal:  Nano Today       Date:  2010-04-01       Impact factor: 20.722

Review 2.  Nanoparticle PEGylation for imaging and therapy.

Authors:  Jesse V Jokerst; Tatsiana Lobovkina; Richard N Zare; Sanjiv S Gambhir
Journal:  Nanomedicine (Lond)       Date:  2011-06       Impact factor: 5.307

Review 3.  Prostate cancer relevant antigens and enzymes for targeted drug delivery.

Authors:  Ashutosh Barve; Wei Jin; Kun Cheng
Journal:  J Control Release       Date:  2014-05-27       Impact factor: 9.776

4.  Folate Receptor-Targeted Polymeric Micellar Nanocarriers for Delivery of Orlistat as a Repurposed Drug against Triple-Negative Breast Cancer.

Authors:  Ramasamy Paulmurugan; Rohith Bhethanabotla; Kaushik Mishra; Rammohan Devulapally; Kira Foygel; Thillai V Sekar; Jeyarama S Ananta; Tarik F Massoud; Abraham Joy
Journal:  Mol Cancer Ther       Date:  2015-11-09       Impact factor: 6.261

5.  Post-coupling strategy enables true receptor-targeted nanoparticles.

Authors:  Jianmeizi Chen; Michael R Jorgensen; Maya Thanou; Andrew D Miller
Journal:  J RNAi Gene Silencing       Date:  2011-09-15

Review 6.  Urokinase-type plasminogen activator receptor (uPAR) as a promising new imaging target: potential clinical applications.

Authors:  Morten Persson; Andreas Kjaer
Journal:  Clin Physiol Funct Imaging       Date:  2013-04-03       Impact factor: 2.273

7.  Lipid-based nanoparticles in cancer diagnosis and therapy.

Authors:  Andrew D Miller
Journal:  J Drug Deliv       Date:  2013-07-09

Review 8.  The many spaces of uPAR: delivery of theranostic agents and nanobins to multiple tumor compartments through a single target.

Authors:  Thomas V O'Halloran; Richard Ahn; Patrick Hankins; Elden Swindell; Andrew P Mazar
Journal:  Theranostics       Date:  2013-06-25       Impact factor: 11.556

9.  A novel tumor targeting drug carrier for optical imaging and therapy.

Authors:  Rui Li; Ke Zheng; Ping Hu; Zhuo Chen; Shanyong Zhou; Jincan Chen; Cai Yuan; Song Chen; Wei Zheng; En Ma; Fengling Zhang; Jinping Xue; Xueyuan Chen; Mingdong Huang
Journal:  Theranostics       Date:  2014-03-24       Impact factor: 11.556

Review 10.  Be Active or Not: the Relative Contribution of Active and Passive Tumor Targeting of Nanomaterials.

Authors:  Rui Li; Ke Zheng; Cai Yuan; Zhuo Chen; Mingdong Huang
Journal:  Nanotheranostics       Date:  2017-07-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.